Menopausal Status Is Another Focus For US FDA Trial Inclusion Efforts
Executive Summary
US FDA is emphasizing the need to assess the effects of menopause on drug safety and efficacy as a continuation of the agency’s efforts to encourage clinical trial sponsors to look more systematically for differences in clinical trial subpopulations.